Open Access. Powered by Scholars. Published by Universities.®
- Discipline
- Institution
Articles 1 - 3 of 3
Full-Text Articles in Medicine and Health Sciences
Nutrition And Prevention Of Alzheimer's Dementia, Arun Swaminathan, Gregory A. Jicha
Nutrition And Prevention Of Alzheimer's Dementia, Arun Swaminathan, Gregory A. Jicha
Neurology Faculty Publications
A nutritional approach to prevent, slow, or halt the progression of disease is a promising strategy that has been widely investigated. Much epidemiologic data suggests that nutritional intake may influence the development and progression of Alzheimer’s dementia (AD). Modifiable, environmental causes of AD include potential metabolic derangements caused by dietary insufficiency and or excess that may be corrected by nutritional supplementation and or dietary modification. Many nutritional supplements contain a myriad of health promoting constituents (anti-oxidants, vitamins, trace minerals, flavonoids, lipids, …etc.) that may have novel mechanisms of action affecting cellular health and regeneration, the aging process itself, or may …
Detection Of Bacterial Antigens And Alzheimer's Disease-Like Pathology In The Central Nervous System Of Balb/C Mice Following Intranasal Infection With A Laboratory Isolate Of Chlamydia Pneumoniae, C. Scott Little Phd, Timothy A. Joyce, Christine Hammond, Hazem Matta, David Cahn, Denah Appelt, Brian J. Balin Phd
Detection Of Bacterial Antigens And Alzheimer's Disease-Like Pathology In The Central Nervous System Of Balb/C Mice Following Intranasal Infection With A Laboratory Isolate Of Chlamydia Pneumoniae, C. Scott Little Phd, Timothy A. Joyce, Christine Hammond, Hazem Matta, David Cahn, Denah Appelt, Brian J. Balin Phd
PCOM Scholarly Papers
Pathology consistent with that observed in Alzheimer’s disease (AD) has previously been documented following intranasal infection of normal wild-type mice with Chlamydia pneumoniae (Cpn) isolated from an AD brain (96-41). In the current study, BALB/c mice were intranasally infected with a laboratory strain of Cpn, AR-39, and brain and olfactory bulbs were obtained at 1-4 months post-infection (pi). Immunohistochemistry for amyloid beta or Cpn antigens was performed on sections from brains of infected or mock-infected mice. Chlamydia-specific immunolabeling was identified in olfactory bulb tissues and in cerebrum of AR-39 infected mice. The Cpn specific labeling was most prominent at 1 …
Clinical Trials And Late-Stage Drug Development In Alzheimer’S Disease: An Appraisal From 1984 To 2014, L. S. Schneider, F. Mangialasche, S. Andreasen, H. Feldman, E. Giacobini, R. Jones, V. Mantua, P. Mecocci, L. Pani, B. Winblad, M. Kivipelto
Clinical Trials And Late-Stage Drug Development In Alzheimer’S Disease: An Appraisal From 1984 To 2014, L. S. Schneider, F. Mangialasche, S. Andreasen, H. Feldman, E. Giacobini, R. Jones, V. Mantua, P. Mecocci, L. Pani, B. Winblad, M. Kivipelto
Human Clinical Trials Collection
The modern era of drug development for Alzheimer's disease began with the proposal of the cholinergic hypothesis of memory impairment and the 1984 research criteria for Alzheimer's disease. Since then, despite the evaluation of numerous potential treatments in clinical trials, only four cholinesterase inhibitors and memantine have shown sufficient safety and efficacy to allow marketing approval at an international level. Although this is probably because the other drugs tested were ineffective, inadequate clinical development methods have also been blamed for the failures. Here, we review the development of treatments for Alzheimer's disease during the past 30 years, considering the drugs, …